Skip to content

Aminophylline for Patients With Post-Dural Puncture Headache

Aminophylline for Patients With Post-Dural Puncture Headache: a Prospective, Multi-center, Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02522013
Enrollment
126
Registered
2015-08-13
Start date
2015-10-31
Completion date
2016-10-31
Last updated
2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-dural Puncture Headache

Keywords

post-dural puncture headache, Aminophylline

Brief summary

Post-dural puncture headache (PDPH) is the most common complication of lumbar puncture. Its clinical manifestations are pain in the forehead and the occipital region, or diffuse headache. The pain is dull or fluctuating, becoming worse when standing and better when lying down, and is often accompanied by symptoms including a stiff neck, tinnitus, hearing loss, photophobia, and nausea, which cause great suffering to the patients1. According to epidemiological data, approximately 10% to 30% of the patients who undergo lumbar puncture suffer from PDPH within 48 hours of the procedure.Currently, commonly used treatments for PDPH include rehydration, the administration of corticotropin, caffeine, or sumatriptan, and the application of an epidural blood patch. The efficacy of theophylline has been proven in a placebo-controlled study in which 17 PDPH patients received an intravenous (IV) injection of 200 mg theophylline. The Visual Analogic Scale scores 4 hours after treatment were significantly different compared with those of the placebo group5. At present, the clinical application of theophylline has been replaced by aminophylline and doxofylline, and it is difficult to purchase theophylline in most hospitals in China and other countries. The Aminophylline for Patients With Post-Dural Puncture Headache trial, is a prospective,randomized,double-blind,placebo-controlled trial to evaluate the efficacy and safety of an IV injection of aminophylline on post-dural puncture headache.Eligible patients were randomized in a blinded fashion(1:1) to receive IV injection of aminophyllineor or sterile isotonic saline.The investigators estimate that this trial will demonstrate that an IV injection of aminophylline could be the preferred method for the clinical treatment of PDPH.

Interventions

DRUGAminophylline
DRUGisotonic saline

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* headache has developed after the dural puncture; * PDPH was defined according to the International Classification of Headache Disorders III (ICHD-3) criteria; * The VAS score of the headache was 5 or more than 5; * age between 18 and 70 years old.

Exclusion criteria

* a previous history of headache that could interfere with PDPH diagnosis; * a history of central nervous system diseases including intracranial hemorrhage, seizures, intracranial hypertension, and hydrocephalus; * a history of cardiovascular system diseases including coronary heart disease, arrhythmias, and hypertension; * a history of peptic ulcer. * women who were pregnant, nursing, or planning a pregnancy.

Design outcomes

Primary

MeasureTime frame
pain on the Visual Analogue Scalebaseline phase

Secondary

MeasureTime frame
the overall response to treatment on the Patient Global Impression of Change2 days after the Intervention

Other

MeasureTime frameDescription
safety (occurrence of adverse reactions)Participants will be followed for the duration of hospital stay, an expected average of 7 daysThe safety of the IV aminophylline treatment for PDPH was evaluated based on the occurrence of adverse reactions

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026